20. November 2009 08:37
Ligand Pharmaceuticals Incorporated today announced that data from a preclinical study on its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation at the 62nd Annual Meeting of the Gerontology Society of America in Atlanta. LGD-4033 exhibited desirable in vivo efficacy on skeletal muscle and bone measurements in animal models of male hypogonadism and postmenopausal osteoporosis.
[More]
f23b18ab-0bd0-4d21-ad99-95fb9aaafa02|0|.0
Posted in: Medical Science News | Medical Condition News
Tags: Anemia, Arthritis, Asthma, Biotechnology, Bone, Bone Mineral Density, Cancer, Cell, Gene Expression, Gerontology, Osteoporosis, Pfizer, Psoriasis, Rheumatoid Arthritis, Sexual Dysfunction, Testosterone
20. November 2009 05:41
The newly discovered Th22 cells are a previously unknown subset of T helper cells. T helper cells are white blood cells that help activate other immune cells when the body is infected by viruses or bacteria. At the same time they help the body to tolerate own tissue and to prevent or curb inflammation.
[More]
19. November 2009 22:41
Ligand Pharmaceuticals Incorporated announced today that it has received $2 million in milestone payments from N. V. Organon, a subsidiary of Merck & Co., Inc., stemming from its research collaboration that is due to expire at the end of December.
[More]
18. November 2009 04:45
Growing use of lasers in surgical and ophthalmic applications, as well as higher number of cosmetic procedures, continues to drive the medical lasers market. Prospects for laser application in cosmetic skin resurfacing appear all the more brighter with growing desire for 'preservation of youth' among the baby boomer generation.
[More]
17. November 2009 08:04
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that Professor John F. Thompson, MD, Professor of Melanoma and Surgical Oncology at the University of Sydney, Director of the Melanoma Institute Australia, and Lead Investigator of the Phase 2 study of PV-10 for Metastatic Melanoma, will be presenting data at the 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers on November 21, 2009 in Berlin, Germany.
[More]
1e4e8117-84c9-490f-b3e0-d09c1aace944|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Apoptosis, Atopic Dermatitis, Breast Cancer, Cancer, Cell, Dermatitis, Dermatology, Evolution, Liver Cancer, Melanoma, Metastasis, Oncology, Psoriasis, Skin Cancer
17. November 2009 06:19
A new type of immune cell that can be out of control in certain chronic inflammatory diseases, worsening the symptoms of conditions like psoriasis and asthma, is described for the first time this week in the Journal of Clinical Investigation.
[More]
17. November 2009 04:14
A seminar on Genetic Screening for Psoriatic Arthritis will be presented on Tuesday, December 8 from 12-1 PM Pacific Standard Time, hosted by pharmacogenomics research and development innovators PsoriasisDX, pioneers of the world’s first genetic test for psoriatic arthritis (PsA). The seminar will feature leading experts Dr. John Koo and Dr. Wilson Liao.
[More]
16. November 2009 07:15
PhotoMedex, Inc. a leading provider of advanced dermatology, clinical skincare and medical laser products, is hosting a free seminar in Indianapolis, IN on November 17, 2009.
[More]
12. November 2009 04:31
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Centocor Ortho Biotech's Stelara, the first interleukin (IL)-12/23 inhibitor to enter the psoriasis drug market in the U.S., is expected to change the prescribing habits of dermatologists and substantially alter patient flow to currently marketed biologic agents, including Amgen's Enbrel and Abbott's Humira.
[More]
11. November 2009 03:21
As competition in the pharmaceutical marketplace grows, companies are increasingly looking towards the drug delivery industry to maximize revenues and combat generic competitors. The search for more efficient drug delivery systems is also being driven by the rise in patient demand, healthcare and pharma cost containment, as much as by medical and technological advances.
[More]
bb603ef9-6d36-47c9-b88c-02946d45ee51|0|.0
Posted in: Device / Technology News
Tags: Acromegaly, Arthritis, Crohn's Disease, Diabetes, Drug Delivery, Hepatitis C, Macular Degeneration, Morphine, Multiple Sclerosis, Nanocrystal, Neutropenia, Oncology, Paliperidone Palmitate, Photodynamic Therapy, Psoriasis, Rheumatoid Arthritis, Rheumatology, Vivitrol
11. November 2009 03:05
QuantumMethod announced today that Lerner Medical Devices, Inc. has selected the firm as agency of record, tasked with branding and launching Levia®, the company's new Personal Targeted Phototherapy™ device for the self-treatment of psoriasis. Levia® enables their patients to target their small area and scalp psoriasis with therapeutic ultraviolet light via proprietary delivery systems designed for precise, fast and safe treatment.
[More]
10. November 2009 07:09
The results of an independent investigator study just published in the online version of Dermatologic Surgery demonstrate that Levulan(®) Photodynamic Therapy (PDT) may reduce the rate of recurrence of squamous cell carcinomas (SCCs) in solid organ transplant recipients (SOTRs), a population with a high incidence of nonmelanoma skin cancer.
[More]
15f24cb5-3991-42d5-97ce-4736aabd2382|0|.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Alopecia, Atopic Dermatitis, Cancer, Cell, Dermatitis, Dermatology, Edema, Melanoma, Microscopy, Photodynamic Therapy, Psoriasis, Skin Cancer, Transplant
6. November 2009 02:15
The Alliance Québécoise du Psoriasis (Quebec psoriasis alliance) would like to give its members and other psoriasis sufferers information concerning the massive H1N1 vaccination campaign.
[More]
6. November 2009 01:08
Ligand Pharmaceuticals Incorporated announced today that its research collaboration with Pfizer for JAK3 has been extended by one year. The Research and License Agreement entered into in December 2006 with Wyeth provided for an initial three year research term. Under this extension, Ligand will receive $3.1 million in research payments to continue conducting drug discovery and lead candidate optimization.
[More]
5. November 2009 01:40
Psoriasis is a real disability that affects approximately one million Canadians. A recent Canadian survey found that the causes and effects of this chronic, recurrent skin disorder are often misunderstood - and the result of these misperceptions can leave a lasting negative impact on those who suffer from this debilitating immune system disease.
[More]
a63f83f5-a942-4e28-a429-389d36c3f6b4|0|.0
Posted in: Medical Condition News
Tags: Anxiety, Arthritis, Biotechnology, Cancer, Depression, Dermatology, Diabetes, Education, Hospital, Hygiene, Kidney Disease, Pfizer, Psoriasis, Rheumatoid Arthritis
Subscribe